[{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Marinomed Biotech \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"STADA Arzneimittel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"STADA Arzneimittel \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Foam","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Jefferies LLC"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Viatris"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Citigroup Global Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Citigroup Global Markets","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Citigroup Global Markets"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Honeywell","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Partnership","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Honeywell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Honeywell \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Honeywell \/ AstraZeneca"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Iconovo","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Amneal Pharmaceuticals \/ Iconovo","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Iconovo"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Mankind Pharma"},{"orgOrder":0,"company":"H&T Presspart","sponsor":"Bilim Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"H&T Presspart","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"H&T Presspart \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"H&T Presspart \/ Bilim Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion LLP \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Symbicort

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Budesonide is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors in cells. It is being investigated for IgA nephropathy.

                          Product Name : D23

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Eohilia (budesonide) is an oral suspension, glucocorticoid receptor agonist, which is approved by USFDA for the treatment of Eosinophilic Esophagitis (EoE).

                          Product Name : TAK-721

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          December 02, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Breztri Aerosphere is a combination of budesonide, glycopyrrolate and formoterol fumarate indicated for the maintenance treatment of patients with COPD.

                          Product Name : Breztri Aerosphere

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          November 23, 2024

                          Lead Product(s) : Budesonide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Nefecon (budesonide) is a patented, oral delayed-release corticosteroid approved for primary IgA nephropathy treatment.

                          Product Name : Nefecon

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          November 03, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Everest Medicines

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.

                          Product Name : Kinpeygo

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          July 26, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Airsupra (albuterol/budesonide) formerly known as PT027, is a first-in-class SABA/ICS. It is being investigated in patients with intermittent or mild persistent asthma.

                          Product Name : Airsupra

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 10, 2024

                          Lead Product(s) : Salbutamol Sulphate,Budesonide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : TARPEYO (budesonide) is an oral, delayed-release formulation for primary IgA nephropathy, utilizing a corticosteroid with potent glucocorticoid activity.

                          Product Name : Nefecon

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          June 03, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Kinpeygo (budesonide), a modified-release capsule, Glucocorticoid receptor agonist, has been approved for primary IgA nephropathy.

                          Product Name : Nefecon

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Nefecon is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, indicated for IgA nephropathy.

                          Product Name : Nefecon

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Nefecon is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, indicated for IgA nephropathy.

                          Product Name : Nefecon

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 07, 2024

                          Lead Product(s) : Budesonide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank